Cardiovascular Institute of the South (CIS) is hosting a free screening on Tuesday, November 14th at our CIS Prairieville location (37292 Market Place Drive, Suite A). Guests will receive a complimentary Electrocardiogram (EKG) and Blood Pressure Screenings. An EKG is a painless test that records the electrical signals of the heart. The screening can detect […]
November 12, 2023 3 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . <button type="button" class="btn btn-primary" data-loading-text="Loading ” data-action=”subscribe”> Subscribe Added to email alerts We were unable to process your request. […]
Outcomes for patients with kidney cancer could benefit due to additional focus on understanding the association between clonal hematopoiesis and cardiovascular health. Further, this association could prove to identify patients with kidney cancer who are at a higher risk of experiencing cardiac events while undergoing treatment, according to Maxine Sun, PhD, MPH.1 “Cardiovascular health is […]
Maxine Sun, PhD, MPH Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events, according to Maxine Sun, PhD, MPH.1 “Cardiovascular health is becoming increasingly important for patients diagnosed with kidney cancer as we are […]
Obesity specialists and cardiologists hailed the results as a turning point with the potential for a “huge population impact.” PHILADELPHIA, PA—Mirroring results in patients with type 2 diabetes, semaglutide (Wegovy; Novo Nordisk) reduces cardiovascular events in patients with overweight or obesity and preexisting CVD who are not diabetic, according to full results of the SELECT […]
In a subset of patients with myocardial infarction and impaired left ventricular systolic function, Farxiga (dapagliflozin) was able to improve cardiometabolic outcomes. This is finding of a registry-based study presented today at the American Heart Association Scientific Sessions meeting in Philadelphia. Stefan James, Ph.D., The cardiometabolic benefit was consistent across subgroups and clinical event rates […]
New data were presented today at the American Heart Association (AHA) annual Scientific Sessions in Philadelphia on SELECT, Novo Nordisk’s (NOV: N) landmark Phase III cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4mg (trade name Wegovy) in adults with established cardiovascular disease (CVD) and overweight or obesity The data were simultaneously published in […]
Novo Nordisk A/S unveiled details from a closely watched study that support use of Wegovy, its blockbuster weight-loss drug, to cut heart attacks and strokes in obesity patients with a history of cardiovascular disease. People taking the highest dose of Wegovy saw a drop in blood sugar levels and inflammation — two harbingers of heart disease […]
November 12, 2023 Cosmos Cosmos is a quarterly science magazine. We aim to inspire curiosity in ‘The Science of Everything’ and make the world of science accessible to everyone. By Cosmos Semaglutide – the active ingredient in diabetes-cum-weightloss drugs Ozempic and Wegovy – might reduce the risk of death from heart disease in overweight people. […]
Novo Nordisk’s NVO, +1.16% popular weight-loss drug Wegovy significantly cut the risk of heart attack, stroke or death due to cardiovascular disease in people who do not have diabetes, according to new data from a large international clinical trial. Patients taking semaglutide, the active ingredient in Wegovy and Ozempic, for more than three years had […]